Form D · Biotechnology
Tune Therapeutics, Inc.
Seattle, WA · CIK 0002053139
Offering snapshot reported Jan 24, 2025 · SEC filing
- Reported sold
- $182M Offering amount: $208M
- Investors reported
- 39 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 9, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 24, 2025 | Initial | $182,414,405 | No comparison | 39 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-536110
Source: Form D, filed Jan 24, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ali Behbahani | Director |
| Charles Gersbach | Director |
| Zachary Hale | Executive |
| Derek Jantz | Executive |
| Akira Matsuno | Executive |
| Dan Mc Hugh | Director, Executive |
| John Mc Hutchison | Director |
| Blythe Sather | Executive |
| Yuan Zhang | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1930 Boren Avenue, Floor 5
Seattle, WA, 98101
Seattle, WA, 98101